dexrazoxane NPPA Approval
Ian Kennedy made this Official Information request to Pharmaceutical Management Agency
This request has an unknown status. We're waiting for Ian Kennedy to read recent responses and update the status.
From: Ian Kennedy
Dear Pharmaceutical Management Agency,
Please can you provide details of the particular clinical circumstance under which an NPPA application for dexrazoxane for use as a cardioprotective agent in the management of osteosarcoma was approved
Yours faithfully,
Ian Kennedy
From: Web Enquiry
Pharmaceutical Management Agency
Thank you for your email. We are looking into your query and will get back
to you as quickly as possible. Please note, our response time may vary
depending on the nature of your request.
We want to know what you think about the way we bring consumer voices into
our work. Will you take a short survey? Visit our website for more
information: https://www.pharmac.govt.nz/about/consum...
**********************************************************************
This email and any files transmitted with it are confidential and
intended solely for the use of the individual or entity to whom they
are addressed. If you have received this email in error please notify
the system manager.
This footnote also confirms that this email message has been swept by
MIMEsweeper for the presence of computer viruses.
www.clearswift.com
**********************************************************************
hide quoted sections
From: Web Enquiry
Pharmaceutical Management Agency
Dear Ian
This email is to acknowledge that your request for information under the
Official Information Act (1982) has been received and is currently being
worked on. We will have a reply to you as soon as possible and no later
than the due date of 5 July 2018.
Kind regards
Dean Zeng
PHARMAC
-----Original Message-----
From: Ian Kennedy [mailto:[FOI #7999 email]]
Sent: Wednesday, June 6, 2018 7:55 PM
To: Web Enquiry <[email address]>
Subject: [SPAM]? Official Information request - dexrazoxane NPPA Approval
Dear Pharmaceutical Management Agency,
Please can you provide details of the particular clinical circumstance
under which an NPPA application for dexrazoxane for use as a
cardioprotective agent in the management of osteosarcoma was approved
Yours faithfully,
Ian Kennedy
-------------------------------------------------------------------
This is an Official Information request made via the FYI website.
Please use this email address for all replies to this request:
[1][FOI #7999 email]
Is [2][PHARMAC request email] the wrong address for Official Information
requests to Pharmaceutical Management Agency? If so, please contact us
using this form:
[3]https://fyi.org.nz/change_request/new?bo...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[4]https://fyi.org.nz/help/officers
If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.
-------------------------------------------------------------------
**********************************************************************
This email and any files transmitted with it are confidential and
intended solely for the use of the individual or entity to whom they
are addressed. If you have received this email in error please notify
the system manager.
This footnote also confirms that this email message has been swept by
MIMEsweeper for the presence of computer viruses.
www.clearswift.com
**********************************************************************
References
Visible links
1. mailto:[FOI #7999 email]
2. mailto:[PHARMAC request email]
3. https://fyi.org.nz/change_request/new?bo...
4. https://fyi.org.nz/help/officers
hide quoted sections
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence